Compounds > n(g)-aminoarginine
Page last updated: 2024-09-03

n(g)-aminoarginine and ro 25-6981

n(g)-aminoarginine has been researched along with ro 25-6981 in 1 studies

Compound Research Comparison

Studies
(n(g)-aminoarginine)		Trials
(n(g)-aminoarginine)		Recent Studies (post-2010)
(n(g)-aminoarginine)		Studies
(ro 25-6981)		Trials
(ro 25-6981)		Recent Studies (post-2010) (ro 25-6981)
21122210137

Protein Interaction Comparison

ProteinTaxonomyn(g)-aminoarginine (IC50)ro 25-6981 (IC50)
Glutamate receptor ionotropic, NMDA 2DHomo sapiens (human)0.006
Glutamate receptor ionotropic, NMDA 3BHomo sapiens (human)0.006
Prolyl endopeptidaseSus scrofa (pig)0.006
Delta-type opioid receptorMus musculus (house mouse)0.006
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)0.0311
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)0.058
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)0.0426
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)0.058
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)0.0315
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)0.006
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)0.024
Glutamate receptor ionotropic, NMDA 2CHomo sapiens (human)0.006
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)0.058
Glutamate receptor ionotropic, NMDA 3AHomo sapiens (human)0.006
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)0.058
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)0.058

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hawker, DD; Jansen Labby, K; Mataka, JJ; Silverman, RB; Trippier, PC1

Reviews

1 review(s) available for n(g)-aminoarginine and ro 25-6981

ArticleYear
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
    Journal of medicinal chemistry, 2013, Apr-25, Volume: 56, Issue:8

    Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antioxidants; Calcium Channels; Drug Combinations; Drug Design; Humans; Huntington Disease; Neurodegenerative Diseases; Nitric Oxide Synthase Type I; Oxidative Stress; Parkinson Disease; Protein Folding; Protein Structure, Quaternary; Proteostasis Deficiencies; Receptors, N-Methyl-D-Aspartate

2013